Letter
Oncology
Yunxin Zeng, Xinyu Zhang, Dongjun Lin, Xiaohui Feng, Yuye Liu, Zhengwen Fang, Weijian Zhang, Yu Chen, Meng Zhao, Jun Wu, Linjia Jiang
Summary: This study revealed that hypoxia environment increases lysosomes in leukemia cells, which in turn reduces the effectiveness of chemotherapy drugs. By developing a novel nanomedicine targeting lysosomes, the researchers were able to enhance the chemotherapy outcome in leukemia. This new approach shows promising results in overcoming chemoresistance in myeloid leukemia.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Article
Engineering, Biomedical
Elena Canato, Antonella Grigoletto, Ilaria Zanotto, Tommaso Tedeschini, Benedetta Campara, Giovanna Quaglio, Giuseppe Toffoli, Delia Mandracchia, Alberto Dinarello, Natascia Tiso, Francesco Argenton, Katia Sayaf, Maria Guido, Daniela Gabbia, Sara De Martin, Gianfranco Pasut
Summary: Liposomes have a significant impact on drug delivery due to their biocompatibility and versatility. The introduction of stealth liposomes, decorated with hydrophilic polyethylene glycol (PEG) molecules, has greatly enhanced the pharmacokinetic profile compared to unmodified liposomes. However, the development of effective targeted liposomes for cancer therapy remains challenging and has experienced clinical failures.
ADVANCED HEALTHCARE MATERIALS
(2023)
Article
Pharmacology & Pharmacy
Daria B. Trushina, Anastasiia Yu Sapach, Olga A. Burachevskaia, Pavel Medvedev, Dmitry N. Khmelenin, Tatiana N. Borodina, Mikhail A. Soldatov, Vera V. Butova
Summary: In this study, biocompatible high-capacity UiO-66 nanoparticles, mesoporous SiO2, and folate-conjugated pluronic F127 were combined to prepare a core-shell UiO-66@SiO2/F127-FA drug delivery carrier for targeted cellular uptake in cancer treatment. The thickness of the SiO2 shell was controlled by varying the duration of silanization, and silica coating improved the colloidal stability of the nanocomposites. Further modification with the conjugate of pluronic and folic acid enhanced biocompatibility and targeted the encapsulated drug to folate-expressing cancer cells.
Article
Chemistry, Inorganic & Nuclear
Yafang Qin, Xingguo Tang, Jintai Chen, Jingcong Huang, Dingding Wang, Xianhuan Zhang, Yangli Zhang, Fenglin Wu, Jinquan Wang
Summary: In this study, a tumor-targeting ruthenium(II) complex, Ru1-LHRH, conjugated with LHRH peptide was synthesized and characterized. Ru1-LHRH selectively targeted the mitochondria of A2780 tumor cells overexpressing LHRH receptor, showing approximately 8 times higher cytotoxicity against A2780 cells compared to non-targeted L02 cells. Moreover, Ru1-LHRH exhibited theranostic functions by simultaneously imaging and killing targeted tumor cells. Further analysis revealed that Ru1-LHRH induced apoptosis by promoting the generation of reactive oxygen species (ROS) and activating the Caspase3/7 protein family. These findings suggest that Ru1-LHRH has potential as a multifunctional tumor-targeted theranostic anticancer agent.
INORGANIC CHEMISTRY COMMUNICATIONS
(2022)
Article
Pharmacology & Pharmacy
Chih-Peng Lin, Shu-Hui Wu, Tzu-Yin Lin, Chia-Hui Chu, Leu-Wei Lo, Ching-Chuan Kuo, Jang-Yang Chang, Szu-Chun Hsu, Bor-Sheng Ko, Ming Yao, Jong-Kai Hsiao, Shih-Wei Wang, Dong-Ming Huang
Summary: This study develops a simple and versatile biological drug delivery system (bDDS) based on human red blood cell-derived vesicles (RDVs), which shows excellent biocompatibility for cancer chemotherapy. The bDDS, named Dox-gluRDVs, effectively suppress multidrug resistance in uterine sarcoma by inducing cell death through a lysosomal-mitochondrial axis-dependent mechanism.
PHARMACOLOGICAL RESEARCH
(2023)
Review
Environmental Sciences
Tenzin Sonam Dongsar, Tenzin Tsering Dongsar, Nagashekhara Molugulu, Sivakumar Annadurai, Shadma Wahab, Neelima Gupta, Prashant Kesharwani
Summary: Breast carcinoma is a diverse disease and one of the most prevalent malignancies in females worldwide. Chemotherapy is widely used for its treatment, but it has limitations. Nanoparticulate systems, particularly PLGA-based nano systems, are being explored as a promising strategy for improving breast carcinoma treatment. This review focuses on the effectiveness of DOX-encapsulated PLGA nanoparticles as a feasible option for breast cancer treatment.
ENVIRONMENTAL RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Ansar Karimian, Bahman Yousefi, Farzin Sadeghi, Farideh Feizi, Hossein Najafzadehvarzi, Hadi Parsian
Summary: The study designed a smart nanocarrier encapsulating doxorubicin to reduce its toxicity on vital organs, especially the heart, through targeted delivery, which also enhances drug release in the acidic environment of cancer cells.
CHEMICO-BIOLOGICAL INTERACTIONS
(2022)
Article
Biochemistry & Molecular Biology
Parisa Maleki Dana, Fatemeh Sadoughi, Russel J. Reiter, Sotoudeh Mohammadi, Zahra Heidar, Masoumeh Mirzamoradi, Zatollah Asemi
Summary: Combination chemotherapy is a beneficial option for cancer patients, but its effectiveness varies. Doxorubicin, a commonly used chemotherapy drug, has serious side effects. Studies suggest that melatonin may serve as an adjuvant to enhance the antitumor effects of Doxorubicin and mitigate its adverse reactions.
Article
Biochemistry & Molecular Biology
Parisa Maleki Dana, Fatemeh Sadoughi, Russel J. Reiter, Sotoudeh Mohammadi, Zahra Heidar, Masoumeh Mirzamoradi, Zatollah Asemi
Summary: Combination chemotherapy can be beneficial for some cancer patients, but not always effective. Doxorubicin is a commonly used chemotherapy drug with serious side effects. Melatonin, a potential anticancer agent, may enhance the antitumor effects of doxorubicin and reduce its side effects.
Article
Pharmacology & Pharmacy
Zihua Zeng, Jianjun Qi, Quanyuan Wan, Youli Zu
Summary: Doxorubicin (DOX) is a common anti-tumor drug that has been utilized to form aptamer-drug conjugates for targeted cancer therapy. The synthesized Apt-TNM-DOX conjugate has high drug payloads and pH-dependent drug release, allowing for specific targeting of lymphoma cells in a simple and non-toxic manner. This targeted therapeutic approach may reduce non-specific side effects associated with traditional chemotherapy.
Article
Materials Science, Biomaterials
Jiayu Yu, Jianing Zhang, Jing Jin, Wei Jiang
Summary: Nanocarriers based on bovine serum albumin and DNA were synthesized for accurate drug delivery and efficient treatment of cancer. One of the nanocarriers showed superior intracellular uptake and cytotoxicity towards cancer cells, demonstrating precise targeting and effective treatment.
JOURNAL OF MATERIALS CHEMISTRY B
(2021)
Article
Pharmacology & Pharmacy
Nastassja Burrini, Mario D'Ambrosio, Matteo Gentili, Roberta Giaquinto, Veronica Settimelli, Cristina Luceri, Marzia Cirri, Oscar Francesconi
Summary: In this study, an amphiphilic analogue of a mannose receptor was developed and used to functionalize niosomes for the encapsulation of doxorubicin. These functionalized niosomes showed high stability, efficient encapsulation of doxorubicin, and enhanced cytotoxicity towards triple-negative breast cancer cells with overexpressed high-mannose-type glycans. Additionally, the niosomal formulation reduced doxorubicin-induced cytotoxicity towards normal cell lines. This study provides a foundation for further in vivo investigations on the antitumoral activity and pharmacokinetics of the developed active targeted drug delivery system.
Article
Oncology
Shoma Yamamoto, Minoru Kato, Yuji Takeyama, Yukari Azuma, Nao Yukimatsu, Yukiyoshi Hirayama, Taiyo Otoshi, Takeshi Yamasaki, Masaki Fujioka, Min Gi, Hideki Wanibuchi, Junji Uchida
Summary: This study aimed to investigate the mechanism of overcoming treatment resistance in immunologically cold tumours by combining radiotherapy (RT) and myeloid-derived suppressor cells (MDSC)-targeted therapy. The results showed that RT can activate lymphocytes but also potentially recruit immunosuppressive cells MDSC. The combination of blocking MDSC and RT can significantly suppress the growth of immunologically cold tumours.
BRITISH JOURNAL OF CANCER
(2023)
Article
Medicine, Research & Experimental
Farshid Maleki, Shahram Rabbani, Reza Shirkoohi, Mohsen Rezaei
Summary: Intravenous mitochondrial transplantation can reduce doxorubicin-induced cardiotoxicity by decreasing ROS production, lipid peroxidation, and inflammation, and increasing ATP and antioxidant enzymes levels, thereby reducing apoptosis and necrosis in heart tissue.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Instruments & Instrumentation
Shunyao Zhu, Xixi Li, Ziyi Luo, Meihong Ding, Senlin Shi, Ting Zhang
Summary: Malignant melanoma is an aggressive skin tumor with increasing incidence and mortality rates worldwide. Chemotherapy drugs have limited effectiveness due to poor sensitivity, side effects, and drug resistance. Liposomes co-loaded with chlorogenic acid and doxorubicin, modified with sialic acid-octadecylamine conjugate, showed robust cellular uptake and improved anti-tumor efficacy in melanoma treatment. The co-delivery of immunomodulatory and chemotherapeutic agents presents a promising therapeutic strategy.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH
(2023)
Article
Cardiac & Cardiovascular Systems
Raul A. Dulce, Rosemeire M. Kanashiro-Takeuchi, Lauro M. Takeuchi, Alessandro G. Salerno, Amarylis C. B. A. Wanschel, Shathiyah Kulandavelu, Wayne Balkan, Marilia S. S. R. Zuttion, Renzhi Cai, Andrew Schally, Joshua M. Hare
Summary: This study aimed to test the hypothesis that activating the GHRH receptor signalling pathway can prevent and reverse diastolic dysfunction and pathophysiologic features associated with HFpEF. The results showed that synthetic GHRH agonists can reduce myocardial fibrosis and hypertrophy, and improve cardiac performance.
CARDIOVASCULAR RESEARCH
(2023)
Meeting Abstract
Oncology
P. Harter, A. du Bois, F. Hilpert, M. Kerkmann, J. Sehouli, S. Mahner, N. de Gregorio, L. Hanker, F. Heitz, F. Marme, L. Woelber, L. Holtmann, G. Elser, J. Pfisterer
ANNALS OF ONCOLOGY
(2022)
Meeting Abstract
Oncology
V. Grunwald, D. Pink, G. Egerer, E. Schalk, M. Augustin, C. K. Deinzer, V. Kob, D. Reichert, M. Kebenko, S. F. Brandl, D. A. Hahn, L. H. Lindner, M. Hoiczyk, U. Ringsdorf, L. Hanker, D. Hempel, M. J. Pontes, T. Wismann, P. Ivanyi
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
Eva Roser, Philipp Harter, Dario Zocholl, Dominik Denschlag, Radoslav Chekerov, Pauline Wimberger, Christian Kurzeder, Annette Hasenburg, Mustafa-Zelal Muallem, Alexander Mustea, Guenter Emons, A. G. Zeimet, Felix Beck, Tjadina Arndt, Sara Y. Brucker, Stefan Kommoss, Florian Heitz, Julia Welz, Eva-Katharina Egger, Matthias Kalder, Paul Buderath, Maximilian Klar, Christian Marth, Uwe Andreas Ulrich, Michael Weigel, Lea Traub, Christoph Anthuber, Hans Strauss, Lars Hanker, Theresa Link, Karol Kubiak, Badrig Melekian, Daniela Hornung, Martin Poelcher, Bjoern Lampe, Thomas Krauss, Ulrich Keilholz, Anne Floercken, Klaus Pietzner, Jalid Sehouli
Summary: This study aimed to describe the treatment strategies used in patients with gynecological sarcomas. The results showed heterogeneous treatment methods, and further research is needed to implement new treatment strategies.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Article
Oncology
Jacobus Pfisterer, Florence Joly, Gunnar Kristensen, Joern Rau, Sven Mahner, Patricia Pautier, Ahmed El-Balat, Jean-Emmanuel Kurtz, Ulrich Canzler, Jalid Sehouli, Martin L. Heubner, Andreas D. Hartkopf, Klaus Baumann, Annette Hasenburg, Lars C. Hanker, Antje Belau, Barbara Schmalfeldt, Dominik Denschlag, Tjoung-Won Park-Simon, Frederic Selle, Christian Jackisch, Alexander Burges, Hans-Joachim Lueck, Guenter Emons, Werner Meier, Martina Gropp-Meier, Willibald Schroeder, Nikolaus de Gregorio, Felix Hilpert, Philipp Harter
Summary: This study aimed to compare standard versus extended duration of bevacizumab treatment for newly diagnosed stage IIB-IV ovarian cancer patients. The results showed that the treatment with bevacizumab for 30 months did not improve progression-free survival (PFS) or overall survival (OS) compared to the standard treatment duration of 15 months.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Marina Boido, Iacopo Gesmundo, Anna Caretto, Francesca Pedrolli, Roberta Schellino, Sheila Leone, Renzhi Cai, Wei Sha, Ezio Ghigo, Andrew V. Schally, Alessandro Vercelli, Riccarda Granata
Summary: The study shows that MR-409 has protective effects on SMN Delta 7 mice, indicating its potential as a promising drug for the treatment of SMA.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2023)
Article
Cardiac & Cardiovascular Systems
Rosemeire M. Kanashiro-Takeuchi, Lauro M. Takeuchi, Raul A. Dulce, Katarzyna Kazmierczak, Wayne Balkan, Renzhi Cai, Wei Sha, Andrew V. Schally, Joshua M. Hare
Summary: HFpEF is a difficult-to-treat condition, but MR-356 may have the potential to improve its phenotypic characteristics, including cardiac hypertrophy, fibrosis, capillary rarefaction, and pulmonary congestion. Additionally, MR-356 can improve diastolic function, global longitudinal strain, exercise capacity, and reduce myocardial stress associated with metabolic inflammation.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
(2023)
Article
Oncology
Pauline Wimberger, Jacobus Pfisterer, Andreas du Bois, Felix Hilpert, Markus Kerkman, Jalid Sehouli, Sven Mahner, Nikolaus de Gregorio, Lars Hanker, Florian Heitz, Frederik Marme, Linn Woelber, Laura Holtmann, Gabriele Elser, Philipp Harter
Summary: This study evaluates the implementation of treatment standards and impact on survival for FIGO stage I ovarian cancer. The results show that although the quality of therapy has improved over the years, not all surgical standards were met in nearly 50% of patients.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Article
Oncology
L. Proppe, T. Jagomast, S. Beume, L. Klapper, G. Gitas, F. Koester, S. Perner, A. Rody, J. Ribbat-Idel, L. C. Hanker
Summary: This study evaluated the prognostic impact of NR2F6 in endometrial cancer and found that NR2F6-positive patients had longer overall survival and progression-free survival, suggesting the important role of NR2F6 in endometrial cancer.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
M. R. Mirza, D. M. Chase, B. M. Slomovitz, R. dePont Christensen, Z. Novak, D. Black, L. Gilbert, S. Sharma, G. Valabrega, L. M. Landrum, L. C. Hanker, A. Stuckey, I. Boere, M. A. Gold, A. Auranen, B. Pothuri, D. Cibula, C. McCourt, F. Raspagliesi, M. S. Shahin, S. E. Gill, B. J. Monk, J. Buscema, T. J. Herzog, L. J. Copeland, M. Tian, Z. He, S. Stevens, E. Zografos, R. L. Coleman, M. A. Powell
Summary: Dostarlimab plus carboplatin-paclitaxel significantly improved progression-free survival in patients with endometrial cancer, particularly in the mismatch repair-deficient microsatellite instability-high population.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Sabine Heublein, Joanna Baum, Anna Jaeger, Donata Grimm-Glang, Julia Olthoff, Elena Ioana Braicu, Osama Azzam Nieto, Kathrin Hassdenteufel, Barbara Schmalfeldt, Lars Hanker, Markus Wallwiener, Andreas Schneeweiss, Jalid Sehouli, Klaus Pietzner
Summary: There is disagreement about the extent of surgical staging and the indication of adjuvant chemotherapy for patients with early-stage ovarian cancer (OC). This study revealed that a significant proportion of early-stage OC patients were not operated on according to the current standard, and highlighted the need for further prospective registries and educational programs to improve clinical management.
Article
Obstetrics & Gynecology
Laura Dussan Molinos, Franziska Fick, Kerstin Muras, Henriette Princk, Lars Hanker, Achim Rody, Maggie Banys-Paluchowski
Summary: Neoadjuvant chemotherapy, with or without antibodies or immunotherapy, is recommended for aggressive breast cancer subtypes before surgery. Achieving pathological complete response (pCR) after neoadjuvant chemotherapy is associated with improved prognosis. Different post-neoadjuvant treatment options are available depending on the tumor biology, including antibody-drug conjugate T-DM1, immunotherapy pembrolizumab, oral chemotherapy capecitabine, and PARP inhibitor olaparib. The post-neoadjuvant strategy for hormone receptor-positive HER2-negative breast cancer is still uncertain. Abemaciclib is recommended for high-risk breast cancer patients in the adjuvant and post-neoadjuvant setting. Olaparib can be administered in patients with a BRCA1/2 mutation and a very high risk of relapse if pCR is not achieved.
Meeting Abstract
Obstetrics & Gynecology
A. Jaeger, M. Hampl, C. Zu Eulenburg, K. Prieske, J. Hambrecht, S. Fuerst, R. Klapdor, S. Heublein, P. Gass, A. Rohner, U. Canzler, S. Becker, M. Bommert, D. Bauerschlag, A. Denecke, L. Hanker, I Runnebaum, D. M. Forner, F. Schochter, M. Klar, R. Schwab, M. Koepke, M. Kalder, P. Hantschmann, D. Ratiu, D. Denschlag, W. Schroeder, B. Tuschy, K. Baumann, A. Mustea, P. Soergel, H. Bronger, G. Bauerschmitz, J. Kosse, M. C. Koch, A. Ignatov, J. Sehouli, C. Dannecker, S. Mahner, L. Woelber
GEBURTSHILFE UND FRAUENHEILKUNDE
(2022)
Meeting Abstract
Obstetrics & Gynecology
N. Jost, K. Milewski, N. Krawczyk, L. Hanker, A. Rody, M. Babys-Paluchowski
GEBURTSHILFE UND FRAUENHEILKUNDE
(2022)
Meeting Abstract
Obstetrics & Gynecology
Authors L. Proppe, J. Ribbat-Idel, S. Beume, F. Hemptenmacher, F. Koester, K. Braeutigam, G. Gitas, A. Rody, S. Perner, L. C. Hanker
GEBURTSHILFE UND FRAUENHEILKUNDE
(2022)